Placenta Growth Factor Gene Expression Is Induced by Hypoxia in Fibroblasts: a Central Role for Metal Transcription Factor-11

Total Page:16

File Type:pdf, Size:1020Kb

Placenta Growth Factor Gene Expression Is Induced by Hypoxia in Fibroblasts: a Central Role for Metal Transcription Factor-11 [CANCER RESEARCH 61, 2696–2703, March 15, 2001] Placenta Growth Factor Gene Expression Is Induced by Hypoxia in Fibroblasts: A Central Role for Metal Transcription Factor-11 Christopher J. Green,2 Peter Lichtlen,2 Nhung T. Huynh, Marianna Yanovsky, Keith R. Laderoute, Walter Schaffner, and Brian J. Murphy3 The Pharmaceutical Discovery Division, SRI International, Menlo Park, California 94025 [C. J. G., N. T. H., M. Y., K. R. L., B. J. M.]; the Institut fur Molekularbiologie der Universitat Zurich, CH-8057 Zurich, Switzerland [W. S.]; and ESBATech AG, CH-8057 Zurich, Switzerland [P. L.] ABSTRACT hPlGF isoforms in that it contains an additional 21 basic amino acid region at the COOH terminus that confers a heparin-binding ability Placenta growth factor (PlGF) is a mitogen for endothelial cells that can similar to that of VEGF (3, 5). However, whereas all VEGF potentiate the growth and permeabilizing effects on endothelium of vas- 165 isoforms bind to the tyrosine kinase receptors flt-1 and KDR/flk-1, cular endothelial growth factor. Here we report that hypoxia induces the PlGF homodimers are believed to bind only to flt-1 (see Ref. 6), expression of both PlGF mRNA and protein in immortalized/transformed mouse embryonic fibroblasts (mEFs) and in NIH 3T3 cells. Importantly, suggesting a role for the homodimers in endothelial cell-cell or the magnitude of the induction of PlGF expression by hypoxia is enhanced cell-matrix interactions (7). PlGF may also potentiate the angiogenic by the presence of oncogenic Ras. To investigate the transcriptional effects of VEGF (8) because the two proteins have the ability to form component of hypoxia-inducible PlGF expression, we cloned and se- heterodimers with each other (2, 9–11) that can activate the KDR/ quenced a 1350-bp fragment of the 5؅-flanking region of the mouse gene. flk-1 receptor (9). Like VEGF, PlGF-2 has also been shown to bind to Analysis of the promoter region indicated the presence of putative con- and activate neuropilin-1 (6, 12), a receptor found on many cell types sensus sequences for known hypoxia-responsive regulatory sites, including in addition to endothelial cells. This receptor can bind at least five metal response elements and Sp1-like sites. In the present study, we show different ligands including VEGF165 and has established roles in a that the induction of PlGF expression by hypoxia is dependent on the wide variety of cellular processes including axonal guidance (13). presence of the metal response element-binding transcription factor 1 These findings suggest that PlGF is a component of extensive com- (MTF-1). Thus, in mEFs with targeted deletions of both MTF-1 alleles, binatorial interactions involving the VEGF superfamily. hypoxia-induced increases of PlGF mRNA and protein levels were greatly In contrast to the widespread distribution of VEGF, PlGF expres- attenuated compared with those in wild-type mEFs. Moreover, transient transfection of a PlGF promoter reporter gene into NIH 3T3 cells resulted sion was originally considered to be restricted to cell types of placen- in hypoxia-responsive transcriptional activation of the reporter. Finally, tal origin such as primary cytotrophoblasts and in vitro differentiated ectopic expression of MTF-1 resulted in increased basal transcriptional syncytiotrophoblasts (e.g., see Ref. 14). However, accumulating evi- activity of a PlGF promoter reporter. Together, these findings demon- dence indicates that PlGF is synthesized in many nonplacental cells strate that the PlGF gene is responsive to hypoxia and that this response and other tissues including human thyroid, brain, lung, and skeletal is mediated by MTF-1. It remains to be determined whether this activa- muscle (reviewed in Ref. 15). PlGF is also highly expressed in dermal tion is the result of direct and/or indirect transcriptional activation by microvascular endothelial cells and retinal pericytes (16), whereas MTF-1. The stimulatory effect of oncogenic Ras on the induction of PlGF conditioned medium from cultured human keratinocytes was found to expression in hypoxic cells suggests that PlGF could be an important contain both PlGF homodimers and PlGF/VEGF heterodimers (11). It proangiogenic factor in the tumor microenvironment. has also been reported that migrating keratinocytes from healing wounds contain significant levels of PlGF from the third to the seventh day after injury (11). Other studies indicate that PlGF may be INTRODUCTION involved in the inflammatory process because PlGF homodimers and PlGF4 is a member of the VEGF family of proangiogenic factors PlGF/VEGF heterodimers were detected in the synovial fluid of (1). Both PlGF and VEGF form glycosylated homodimers that share patients with inflammatory arthopathies (17). PlGF is also expressed significant homology at the amino acid level within their platelet- in several types of solid tumors (18–21). Furthermore, PlGF is be- derived growth factor-like regions, including the conservation of eight lieved to be involved in the pathogenesis of PDR and other ischemic cysteine residues involved in intra- and interchain disulfide bond retinal diseases (22–24). formation (1, 2). hPlGF is also similar to VEGF (and platelet-derived Oxygen deprivation (hypoxia) appears to be a common feature of growth factor) in that alternative splicing of the mRNA from a single many of the pathophysiological conditions in which PLGF is ex- copy gene produces different isoforms of the protein [PlGF-1, PlGF-2, pressed. For example, hypoxia is a characteristic common to many solid tumors and is believed to contribute to increased expression of and PlGF-3 (3, 4)]. PlGF-2, or PlGF170, differs from the other two proangiogenic proteins (e.g., VEGF) and subsequent activation of angiogenesis (25, 26). However, the role of hypoxia in the regulation Received 9/7/00; accepted 1/12/01. The costs of publication of this article were defrayed in part by the payment of page of PlGF expression is currently unclear because the majority of cell charges. This article must therefore be hereby marked advertisement in accordance with lines used to examine its expression appear to be unresponsive to 18 U.S.C. Section 1734 solely to indicate this fact. 1 Supported by NCI Grants CA57692 (to B. J. M.) and CA73807 and CA67166 (to oxygen deprivation (10, 16, 27, 28). The findings presented here K. R. L.). demonstrate that immortalized/transformed fibroblasts express PlGF 2 C. J. G. and P. L. contributed equally to these studies. and that exposure of these cells to physiologically relevant levels of 3 To whom requests for reprints should be addressed, at The Pharmaceutical Discovery Division, SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025. Phone: hypoxia results in significant inductions of the steady-state levels of (650) 859-4213; Fax: (650) 859-5816; E-mail: [email protected]. both PlGF mRNA and protein. We also show that this activation is 4 The abbreviations used are: PlGF, placental growth factor; hPlGF, human PlGF; mPlGF, mouse PlGF; HRE, hypoxia response element; MRE, metal response element; dependent on the presence of the redox-sensitive transcription factor MT, metallothionein; MTF-1, metal response element-binding transcription factor 1; MTF-1 (29, 30) and that the hypoxia-inducible increase in PlGF PDR, proliferative diabetic retinopathy; RT-PCR, reverse transcription-PCR; VEGF, vascular endothelial growth factor; mEF, mouse embryonic fibroblast; Tag, T antigen; expression is due at least in part to increased transcription of the PlGF CMV, cytomegalovirus. gene, particularly in the presence of oncogenic ras. 2696 Downloaded from cancerres.aacrjournals.org on September 26, 2021. © 2001 American Association for Cancer Research. PlGF INDUCTION BY HYPOXIA IS MTF-1 DEPENDENT MATERIALS AND METHODS been cleaved with a variety of restriction enzymes and ligated with linkers containing primer sites for PCR amplification. Two nested PCR primers Cell Culture and Hypoxia. All cell cultures, including mEFs and NIH complementary to the 5Ј-end of the longest known mouse cDNA for PlGF 3T3, JAR (a human choriocarcinoma cell line), and HepG2 (a human hepa- (GenBank accession number X96793) were used. The two primers were toma cell line) cells, were maintained in DMEM containing 10% dialyzed fetal complementary to bases 268–291 and 295–318 of this cDNA sequence. Only bovine serum. Both SV40 large TAg and TAg/Ras-transformed wild-type one 500-bp fragment was obtained using this kit. Because only slightly more ϩ/ϩ Ϫ/Ϫ (MTF-1 ) and MTF-1 null (MTF-1 ) mEFs were used in these studies. To than 200 bp of this sequence were from the upstream region of the known obtain the mEFs, primary embryonic fibroblasts were isolated from 12.5-day- mPlGF cDNA, it was considered unlikely that this fragment would contain all old mouse embryos using standard techniques (31). PCR genotyping for of the necessary regulatory elements to function as a promoter in reporter gene MTF-1 null cells was performed using genomic DNA prepared from yolk sacs studies. Therefore, inverse PCR was used to clone a larger sequence of the and early passages of the primary cells. Wild-type and MTF-1 null primary mPlGF gene. Mouse genomic DNA (1 ␮g) was cleaved with BamHI, EcoRI, cells were then transfected with either 10 ␮g of plasmid CMV-TAg or 10 ␮g HindIII, KpnI, SstI, or XbaI. Each of the cleaved DNA preparations was of plasmid CMV-TAg and 10 ␮g of plasmid c-H-ras(A) (32) per 100-mm- dissolved in 0.5 ml of 50 mM Tris-HCl (pH 7.8), 10 mM MgCl2,20mM DTT, diameter cell culture plate. The plasmid CMV-TAg directs expression of TAg, and1mM ATP, and then 2 units of T4 DNA ligase (Life Technologies, Inc., and c-H-ras(A) directs expression of oncogenic human H-ras. Cell foci were Rockville, MD) were added. The ligation reactions were then incubated at 5°C isolated, and immortalized cell lines were derived.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0111743 A1 Takahashi (43) Pub
    US 200901 11743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0111743 A1 Takahashi (43) Pub. Date: Apr. 30, 2009 (54) CYSTEINE-BRANCHED HEPARIN-BINDING Related U.S. Application Data GROWTH FACTOR ANALOGS (60) Provisional application No. 60/656,713, filed on Feb. 25, 2005. (75) Inventor: Kazuyuki Takahashi, O O Germantown, MD (US) Publication Classification (51) Int. Cl. Correspondence Address: A638/08C07K 700 30.82006.O1 201 THIRD STREET, N.W., SUITE 1340 A638/16 (2006.01) ALBUQUEROUE, NM 87102 (US) A638/10 (2006.01) A638/00 (2006.01) (73) Assignee: BioSurface Engineering (52) U.S. Cl. ........... 514/12:530/330; 530/329; 530/328; Technologies, Inc., Rockville, MD 530/327: 530/326; 530/325; 530/324; 514/17; (US) 514/16; 514/15: 514/14: 514/13 (57) ABSTRACT (21) Appl. No.: 11/362,137 The present invention provides a heparin binding growth factor analog of any of formula I-VIII and methods and uses (22) Filed: Feb. 23, 2006 thereof. US 2009/011 1743 A1 Apr. 30, 2009 CYSTENE-BRANCHED HEPARN-BINDING 0007 HBGFs useful in prevention or therapy of a wide GROWTH FACTOR ANALOGS range of diseases and disorders may be purified from natural sources or produced by recombinant DNA methods, however, CROSS-REFERENCE TO RELATED Such preparations are expensive and generally difficult to APPLICATIONS prepare. 0008. Some efforts have been made to generate heparin 0001. This application claims priority to and the benefit of binding growth factor analogs. For example, natural PDGF the filing of U.S. Provisional Patent Application Ser.
    [Show full text]
  • Angiocrine Endothelium: from Physiology to Cancer Jennifer Pasquier1,2*, Pegah Ghiabi2, Lotf Chouchane3,4,5, Kais Razzouk1, Shahin Rafi3 and Arash Rafi1,2,3
    Pasquier et al. J Transl Med (2020) 18:52 https://doi.org/10.1186/s12967-020-02244-9 Journal of Translational Medicine REVIEW Open Access Angiocrine endothelium: from physiology to cancer Jennifer Pasquier1,2*, Pegah Ghiabi2, Lotf Chouchane3,4,5, Kais Razzouk1, Shahin Rafi3 and Arash Rafi1,2,3 Abstract The concept of cancer as a cell-autonomous disease has been challenged by the wealth of knowledge gathered in the past decades on the importance of tumor microenvironment (TM) in cancer progression and metastasis. The sig- nifcance of endothelial cells (ECs) in this scenario was initially attributed to their role in vasculogenesis and angiogen- esis that is critical for tumor initiation and growth. Nevertheless, the identifcation of endothelial-derived angiocrine factors illustrated an alternative non-angiogenic function of ECs contributing to both physiological and pathological tissue development. Gene expression profling studies have demonstrated distinctive expression patterns in tumor- associated endothelial cells that imply a bilateral crosstalk between tumor and its endothelium. Recently, some of the molecular determinants of this reciprocal interaction have been identifed which are considered as potential targets for developing novel anti-angiocrine therapeutic strategies. Keywords: Angiocrine, Endothelium, Cancer, Cancer microenvironment, Angiogenesis Introduction of blood vessels in initiation of tumor growth and stated Metastatic disease accounts for about 90% of patient that in the absence of such angiogenesis, tumors can- mortality. Te difculty in controlling and eradicating not expand their mass or display a metastatic phenotype metastasis might be related to the heterotypic interaction [7]. Based on this theory, many investigators assumed of tumor and its microenvironment [1].
    [Show full text]
  • Type of the Paper (Article
    Table S1. Gene expression of pro-angiogenic factors in tumor lymph nodes of Ibtk+/+Eµ-myc and Ibtk+/-Eµ-myc mice. Fold p- Symbol Gene change value 0,007 Akt1 Thymoma viral proto-oncogene 1 1,8967 061 0,929 Ang Angiogenin, ribonuclease, RNase A family, 5 1,1159 481 0,000 Angpt1 Angiopoietin 1 4,3916 117 0,461 Angpt2 Angiopoietin 2 0,7478 625 0,258 Anpep Alanyl (membrane) aminopeptidase 1,1015 737 0,000 Bai1 Brain-specific angiogenesis inhibitor 1 4,0927 202 0,001 Ccl11 Chemokine (C-C motif) ligand 11 3,1381 149 0,000 Ccl2 Chemokine (C-C motif) ligand 2 2,8407 298 0,000 Cdh5 Cadherin 5 2,5849 744 0,000 Col18a1 Collagen, type XVIII, alpha 1 3,8568 388 0,003 Col4a3 Collagen, type IV, alpha 3 2,9031 327 0,000 Csf3 Colony stimulating factor 3 (granulocyte) 4,3332 258 0,693 Ctgf Connective tissue growth factor 1,0195 88 0,000 Cxcl1 Chemokine (C-X-C motif) ligand 1 2,67 21 0,067 Cxcl2 Chemokine (C-X-C motif) ligand 2 0,7507 631 0,000 Cxcl5 Chemokine (C-X-C motif) ligand 5 3,921 328 0,000 Edn1 Endothelin 1 3,9931 042 0,001 Efna1 Ephrin A1 1,6449 601 0,002 Efnb2 Ephrin B2 2,8858 042 0,000 Egf Epidermal growth factor 1,726 51 0,000 Eng Endoglin 0,2309 467 0,000 Epas1 Endothelial PAS domain protein 1 2,8421 764 0,000 Ephb4 Eph receptor B4 3,6334 035 V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 0,000 Erbb2 3,9377 neuro/glioblastoma derived oncogene homolog (avian) 024 0,000 F2 Coagulation factor II 3,8295 239 1 0,000 F3 Coagulation factor III 4,4195 293 0,002 Fgf1 Fibroblast growth factor 1 2,8198 748 0,000 Fgf2 Fibroblast growth factor
    [Show full text]
  • Targeting Fibroblast Growth Factor Pathways in Endometrial Cancer
    Curr Probl Cancer 41 (2017) 37–47 Contents lists available at ScienceDirect Curr Probl Cancer journal homepage: www.elsevier.com/locate/cpcancer Targeting fibroblast growth factor pathways in endometrial cancer Boris Winterhoff, MDa, Gottfried E. Konecny, MDb,* article info abstract Novel treatments that improve outcomes for patients with Keywords: recurrent or metastatic endometrial cancer (EC) remain an Endometrial cancer unmet need. Aberrant signaling by fibroblast growth factors Fibroblast growth factor (FGFs) and FGF receptors (FGFRs) has been implicated in Angiogenesis several human cancers. Activating mutations in FGFR2 have been found in up to 16% of ECs, suggesting an opportunity for targeted therapy. This review summarizes the role of the FGF pathway in angiogenesis and EC, and provides an overview of FGFR-targeted therapies under clinical develop- ment for the treatment of EC. & 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Introduction Endometrial cancer (EC) is the most common gynecologic cancer, with 54,870 new cases and 10,170 related deaths estimated for the United States in 2015.1 Localized disease is often curable with surgery and the 5-year relative survival rate for patients diagnosed with early-stage EC is high.1-3 However, for patients who present with metastatic disease or experience a recurrence, prognosis is poor.1-3 Response of metastatic EC to standard therapies (eg, adjuvant radiotherapy, brachytherapy, or chemotherapy) is limited and overall survival for most patients with recurrent or metastatic disease is r1year.2-4 Thus, novel treatment options for this disease remain an unmet need.
    [Show full text]
  • Investigating Hypoxic Tumor Physiology Through Gene Expression Patterns
    Oncogene (2003) 22, 5907–5914 & 2003 Nature Publishing Group All rights reserved 0950-9232/03 $25.00 www.nature.com/onc Investigating hypoxic tumor physiology through gene expression patterns Nicholas C Denko*,1, Lucrezia A Fontana1, Karen M Hudson1, Patrick D Sutphin1, Soumya Raychaudhuri2, Russ Altman2 and Amato J Giaccia1 1Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; 2Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA Clinical evidence shows that tumor hypoxia is an relyupon oxygen-dependent energyproduction suffer independent prognostic indicator of poor patient outcome. when oxygen falls below a certain threshold level. Hypoxic tumors have altered physiologic processes, However, too much oxygen can also result in the including increased regions of angiogenesis, increased generation of toxic, damaging radical byproducts. The local invasion, increased distant metastasis and altered net effect of these opposing pressures necessitates apoptotic programs. Since hypoxia is a potent controller the evolution of molecular mechanisms to regulate the of gene expression, identifying hypoxia-regulated genes is cellular availabilityand usage of oxygen. a means to investigate the molecular response to hypoxic The response to low-oxygen conditions has been stress. Traditional experimental approaches have identi- identified in both procaryotes and eucaryotes. Although fied physiologic changes in hypoxic cells. Recent studies the mechanisms for gene regulation in response to low- have identified hypoxia-responsive genes that may define oxygen conditions are diverse, parallel systems have the mechanism(s) underlying these physiologic changes. evolved in different organisms that are transcriptionally For example, the regulation of glycolytic genes by responsive to low-oxygen.
    [Show full text]
  • Endothelial Cells and VEGF in Vascular Development Leigh Coultas1, Kallayanee Chawengsaksophak1 & Janet Rossant1
    Insight Rossant p7-15 6/12/05 10:23 AM Page 9377 INSIGHT REVIEW NATURE|Vol 438|15 December 2005|doi:10.1038/nature04479 Endothelial cells and VEGF in vascular development Leigh Coultas1, Kallayanee Chawengsaksophak1 & Janet Rossant1 The intricate patterning processes that establish the complex vascular system during development depend on a combination of intrinsic pre-patterning and extrinsic responses to environmental parameters. Mutational studies in mice and fish have shown that the vascular system is highly sensitive to genetic disruption and have identified potential targets for therapeutic interventions. New insights into non-vascular roles of vascular endothelial growth factor and the requirement for endothelial cells in adult organs and stem- cell niches highlight possible side effects of anti-angiogenic therapy and the need for new targets. The development of the vascular system is one of the earliest events are essential for vascular development has been compiled and is in organogenesis. The early blood vessels of the embryo and yolk given in Supplementary Table 1. sac in mammals develop by aggregation of de-novo-forming Endothelial cells might probably have more interesting roles than angioblasts into a primitive vascular plexus (vasculogenesis), just acting as channels for blood circulation. They can promote stem- which then undergoes a complex remodelling process, in which cell development and organ formation by acting as sources of growth, migration, sprouting and pruning lead to the development of a functional circulatory system (angiogenesis; Fig. 1). Many of the events that occur during the normal progression of vascular development in the embryo are recapitulated during situations of neoangiogenesis in the adult1.
    [Show full text]
  • Vascular Endothelial Growth Factor (VEGF) Signaling in Tumor Progression Robert Roskoski Jr
    Critical Reviews in Oncology/Hematology 62 (2007) 179–213 Vascular endothelial growth factor (VEGF) signaling in tumor progression Robert Roskoski Jr. ∗ Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116A, Box 19, Horse Shoe, NC 28742, USA Accepted 29 January 2007 Contents 1. Vasculogenesis and angiogenesis....................................................................................... 180 1.1. Definitions .................................................................................................... 180 1.2. Physiological and non-physiological angiogenesis ................................................................. 181 1.3. Activators and inhibitors of angiogenesis ......................................................................... 181 1.4. Sprouting and non-sprouting angiogenesis ........................................................................ 181 1.5. Tumor vessel morphology....................................................................................... 183 2. The vascular endothelial growth factor (VEGF) family ................................................................... 183 3. Properties and expression of the VEGF family .......................................................................... 183 3.1. VEGF-A ...................................................................................................... 183 3.2. VEGF-B ...................................................................................................... 185 3.3. VEGF-C .....................................................................................................
    [Show full text]
  • Figure S1. Reverse Transcription‑Quantitative PCR Analysis of ETV5 Mrna Expression Levels in Parental and ETV5 Stable Transfectants
    Figure S1. Reverse transcription‑quantitative PCR analysis of ETV5 mRNA expression levels in parental and ETV5 stable transfectants. (A) Hec1a and Hec1a‑ETV5 EC cell lines; (B) Ishikawa and Ishikawa‑ETV5 EC cell lines. **P<0.005, unpaired Student's t‑test. EC, endometrial cancer; ETV5, ETS variant transcription factor 5. Figure S2. Survival analysis of sample clusters 1‑4. Kaplan Meier graphs for (A) recurrence‑free and (B) overall survival. Survival curves were constructed using the Kaplan‑Meier method, and differences between sample cluster curves were analyzed by log‑rank test. Figure S3. ROC analysis of hub genes. For each gene, ROC curve (left) and mRNA expression levels (right) in control (n=35) and tumor (n=545) samples from The Cancer Genome Atlas Uterine Corpus Endometrioid Cancer cohort are shown. mRNA levels are expressed as Log2(x+1), where ‘x’ is the RSEM normalized expression value. ROC, receiver operating characteristic. Table SI. Clinicopathological characteristics of the GSE17025 dataset. Characteristic n % Atrophic endometrium 12 (postmenopausal) (Control group) Tumor stage I 91 100 Histology Endometrioid adenocarcinoma 79 86.81 Papillary serous 12 13.19 Histological grade Grade 1 30 32.97 Grade 2 36 39.56 Grade 3 25 27.47 Myometrial invasiona Superficial (<50%) 67 74.44 Deep (>50%) 23 25.56 aMyometrial invasion information was available for 90 of 91 tumor samples. Table SII. Clinicopathological characteristics of The Cancer Genome Atlas Uterine Corpus Endometrioid Cancer dataset. Characteristic n % Solid tissue normal 16 Tumor samples Stagea I 226 68.278 II 19 5.740 III 70 21.148 IV 16 4.834 Histology Endometrioid 271 81.381 Mixed 10 3.003 Serous 52 15.616 Histological grade Grade 1 78 23.423 Grade 2 91 27.327 Grade 3 164 49.249 Molecular subtypeb POLE 17 7.328 MSI 65 28.017 CN Low 90 38.793 CN High 60 25.862 CN, copy number; MSI, microsatellite instability; POLE, DNA polymerase ε.
    [Show full text]
  • Assessment of Plasma Cytokine Profile Changes in Bevacizumab
    Biochemistry and Molecular Biology Assessment of Plasma Cytokine Profile Changes in Bevacizumab-Treated Retinopathy of Prematurity Infants Lingkun Kong,1 Ann B. Demny,2 Ahmar Sajjad,1 Amit R. Bhatt,1 and Sridevi Devaraj3 1Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, United States 2Department of Pediatrics, Baylor College of Medicine, Houston, Texas, United States 3Department of Clinical Pathology, Baylor College of Medicine, Houston, Texas, United States Correspondence: Lingkun Kong, De- PURPOSE. We compared changes of plasma angiogenesis cytokine profiles in infants who were partment of Ophthalmology, Baylor treated with intravitreal injection of bevacizumab (IVB) for type 1 retinopathy of prematurity College of Medicine, 6701 Fannin (ROP) with age-matched preterm non-ROP infants. Street,Suite610.25,Houston,TX 77030, USA; METHODS. Thirteen infants with type 1 ROP and 13 age-matched preterm non-ROP infants [email protected]. were included. Blood samples were collected prior to treatment (time 0) and 6 weeks after Submitted: October 28, 2015 the treatment (time 42). Plasma levels of nine cytokines from the angiogenesis growth factor Accepted: February 21, 2016 panel and seven soluble cytokine receptors were measured using a magnetic multiplex assay. Citation: Kong L, Demny AB, Sajjad A, RESULTS. Plasma cytokine profiles changed from time 0 to time 42 in both groups. In Bhatt AR, Devaraj S. Assessment of bevacizumab-treated ROP infants, the following plasma angiogenesis growth factor and plasma cytokine profile changes in soluble cytokine receptor levels decreased significantly: soluble VEGF-A (sVEGF-A; P ¼ bevacizumab-treated retinopathy of 0.0001), sVEGF-D (P ¼ 0.04), angiopoietin-2 (Ang-2; P ¼ 0.002), sVEGF receptor 1 (R1) and prematurity infants.
    [Show full text]
  • Plgf) in the Antitumor Immune Response and Cancer Progression
    International Journal of Molecular Sciences Review Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression Loredana Albonici *, Maria Gabriella Giganti, Andrea Modesti, Vittorio Manzari and Roberto Bei Department of Clinical Sciences and Translational Medicine, University of Rome “Tor Vergata”, Via Montpellier 1, 00133 Rome, Italy; [email protected] (M.G.G.); [email protected] (A.M.); [email protected] (V.M.); [email protected] (R.B.) * Correspondence: [email protected] Received: 8 May 2019; Accepted: 14 June 2019; Published: 18 June 2019 Abstract: The sharing of molecules function that affects both tumor growth and neoangiogenesis with cells of the immune system creates a mutual interplay that impairs the host’s immune response against tumor progression. Increasing evidence shows that tumors are able to create an immunosuppressive microenvironment by recruiting specific immune cells. Moreover, molecules produced by tumor and inflammatory cells in the tumor microenvironment create an immunosuppressive milieu able to inhibit the development of an efficient immune response against cancer cells and thus fostering tumor growth and progression. In addition, the immunoediting could select cancer cells that are less immunogenic or more resistant to lysis. In this review, we summarize recent findings regarding the immunomodulatory effects and cancer progression of the angiogenic growth factor namely placental growth factor (PlGF) and address the biological complex effects of this cytokine. Different pathways of the innate and adaptive immune response in which, directly or indirectly, PlGF is involved in promoting tumor immune escape and metastasis will be described. PlGF is important for building up vascular structures and functions.
    [Show full text]
  • Placental Growth Factor As a Marker of Fetal Growth Restriction Caused by Placental Dysfunction
    Placenta 42 (2016) 1e8 Contents lists available at ScienceDirect Placenta journal homepage: www.elsevier.com/locate/placenta Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction * Samantha J. Benton a, , Lesley M. McCowan b, Alexander E.P. Heazell c, David Grynspan d, Jennifer A. Hutcheon a, Christof Senger e, Orlaith Burke f, Yuen Chan b, Jane E. Harding g, Julien Yockell-Lelievre h, Yuxiang Hu a, Lucy C. Chappell i, Melanie J. Griffin i, Andrew H. Shennan i, Laura A. Magee a, 1, Andree Gruslin j, 2, Peter von Dadelszen a, 1 a Department of Obstetrics and Gynaecology, Faculty of Medicine, University of British Columbia, 4500 Oak Street, Vancouver, British Columbia, V6H 3N1, Canada b Department of Obstetrics and Gynaecology, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand c Maternal and Fetal Health Research Centre, University of Manchester, 5th Floor, St. Mary's Hospital, Oxford Road, Manchester, M13 9WL, United Kingdom d Department of Pathology, Children's Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, Ontario, K1H 8L1, Canada e Department of Pathology, Children's and Women's Health Centre of British Columbia, 4500 Oak Street, Vancouver, British Columbia, V6H 2N9, Canada f Nuffield Department of Population Health, Institute of Health Sciences, University of Oxford, Old Road, Oxford, OX3 7LF, United Kingdom g Liggins Institute, University of Auckland, Private Bag 92019, Victoria Street West, Auckland, 1142, New Zealand h Sprott
    [Show full text]
  • List of Predicted Circfam120a Target Mrnas Gene in Pathway Species Gene Name
    List of predicted circFAM120A target mRNAs Gene in pathway Species Gene name HRAS Homo sapiens HRas proto-oncogene, GTPase (HRAS) ADCY1 Homo sapiens Adenylate cyclase 1 (ADCY1) ADCY2 Homo sapiens Adenylate cyclase 2 (ADCY2) ADCY7 Homo sapiens Adenylate cyclase 7 (ADCY7) PTGS2 Homo sapiens Prostaglandin-endoperoxide synthase 2 (PTGS2) PGF Homo sapiens Placental growth factor (PGF) ADCY5 Homo sapiens Adenylate cyclase 5 (ADCY5) STAT5A Homo sapiens Signal transducer and activator of transcription 5A (STAT5A) ADCY6 Homo sapiens Adenylate cyclase 6 (ADCY6) STAT5B Homo sapiens Signal transducer and activator of transcription 5B (STAT5B) LPAR3 Homo sapiens Lysophosphatidic acid receptor 3 (LPAR3) LPAR2 Homo sapiens Lysophosphatidic acid receptor 2 (LPAR2) CTNNB1 Homo sapiens Catenin beta 1 (CTNNB1) CUL2 Homo sapiens Cullin 2 (CUL2) RARA Homo sapiens Retinoic acid receptor alpha (RARA) GNG2 Homo sapiens G protein subunit gamma 2 (GNG2) RARB Homo sapiens Retinoic acid receptor beta (RARB) GNG3 Homo sapiens G protein subunit gamma 3 (GNG3) FAS Homo sapiens Fas cell surface death receptor (FAS) GNG4 Homo sapiens G protein subunit gamma 4 (GNG4) GNG7 Homo sapiens G protein subunit gamma 7 (GNG7) PIK3CG Homo sapiens Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (PIK3CG) WNT10B Homo sapiens Wnt family member 10B (WNT10B) BCR Homo sapiens BCR, RhoGEF and GTPase activating protein (BCR) BRAF Homo sapiens B-Raf proto-oncogene, serine/threonine kinase (BRAF) RXRB Homo sapiens Retinoid X receptor beta (RXRB) ROCK2 Homo sapiens Rho
    [Show full text]